

TRACK RECORD OF THE PUBLIC ISSUES MANAGED BY THE MERCHANT BANKER IN THE LAST 3 FINANCIAL YEARS

Name of the Issue:	Tarsons Products Limited
1. Type of Issue (IPO/FPO)	IPO
2. Issue Size (Rs. Cr)	INR 1023.474 Cr
3. Grade of issue along with name of the rating a	agency
Name	ΝΑ
Grade	NA
4. Subscription Level (Number of times)	The Offer was subscribed 76.39 times (excluding the Anchor Investor Portion and after removing multiple and duplicate bids and technical rejection cases) *

*Source - Minutes of Basis of Allotment dated November 23, 2021

5. QIB Holding (as a % of outstanding capital) as disclosed to stock exchanges

Particulars	Percentage
(i) allotment in the issue	14.49*
(ii) at the end of the 1st Quarter immediately after the listing of the issue^^	15.66
(iii) at the end of 1st FY (March 31, 2022) ^{*}	16.88
(iv) at the end of 2nd FY (March 31, 2023)#	17.60
(v) at the end of 3rd FY (March 31, 2024)##	8.34

(*) As a % of total post issue paid up capital as per Prospectus dated November 18, 2021 ^ Shareholding Pattern filed with Stock Exchange for the quarter ended December 31, 2021 ^* Shareholding Pattern filed with Stock Exchange for the quarter ended March 31, 2022 # Shareholding Pattern filed with Stock Exchange for the quarter ended March 31, 2023 ## Shareholding Pattern filed with Stock Exchange for the quarter ended March 31, 2023



6. Financials of the issuer (as per the annual financial results submitted to stock exchanges)

Consolidated			(Rs in Crores)
Parameters	1st FY (March 31, 2022)**	2nd FY (March 31, 2023)#	3rd FY (March 31, 2024)##
Income from operations	300.79	283.24	296.39
Net Profit for the period	100.66	80.71	42.64
Paid-up equity share capital	10.64	10.64	10.64
Reserves excluding revaluation reserves	479.18	558.66	602.22

** Source: Financial Statements as submitted to the Stock Exchange for the financial year ended March 31, 2022

Source: Financial Statements as submitted to the Stock Exchange for the financial year ended March 31, 2023

Source: Financial Statements as submitted to the Stock Exchange for the financial year ended March 31, 2024

7. Trading Status in the scrip of the issuer

Company's Equity Shares are listed on both the BSE Limited and the National Stock Exchange of India Limited.

Particulars	Status
(i) at the end of 1st FY (March 31, 2022)	Frequently Traded
(ii) at the end of 2nd FY (March 31, 2023)	Frequently Traded
(iii) at the end of 3rd FY (March 31, 2024)	Frequently Traded

* Trading status not disclosed as reporting for the relevant fiscal years has not been completed Source : Stock Exchange.

8. Change in Directors of issuer from the disclosures in the offer document

Particulars	Name of the Director	Appointed / Resigned
(i) at the end of 1st FY (March 31, 2022)	None	None
(ii) at the end of 2nd FY (March 31, 2023)	None	None
(iii) at the end of 3rd FY (March 31, 2024)*	None	None

The changes in the Directors have been updated till May 30, 2024.



9. Status of implementation of project/ commencement of commercial production

(i) As disclosed in the offer document:

Proposed schedule of implementation of the Proposed Expansion

Particulars of activities	Estimated date of commencement	Estimated date of completion
Land acquisition	Completed	Completed
Statutory clearances / approvals	October 1, 2021	January 31, 2023
Civil design and construction	October 1, 2021	January 31, 2023
Engineering and procurement	October 1, 2021	November 30, 2022
Erection and pre- commissioning activities	August 1, 2022	July 31, 2023
Commissioning	August 1, 2023	

(ii) Actual implementation:

Delay in implementation of the object(s):

Object(s) Name	Particulars of activities	Completion Date		Delay (No. of days/ months)		
		As per Offer Document	Actual		Reason of delay	Proposed Course of Action
Funding Capital	Civil design & construction	31/01/2023	31/07/2023	6 months	Unforeseen delay in	The construction
Expenditure for the purposed Expansion	Erection and pre commissioning activities	31/07/2023	31/01/2024	6 months	and delay in receiving the machineries /moulds.	has been completed within July 2023 and production should be started within July 2024
	Commissioning commencement	01/08/2023	31/01/2024	6 months		

(iii) Reasons for delay in implementation, if any: Refer above table

Source: Monitoring Agency Report dated May 9, 2024 for the quarter ended on March 31, 2024.



10. Status of utilization of issue proceeds

(i) As disclosed in the offer document:

				Rs. In million
Particulars	Total estimated cost	AmounttobefundedfromtheNet Proceeds	Estimated deployn Proceeds	nent of the Net
			Fiscal 2022	Fiscal 2023
Repayment/prepayment of certain borrowings of our Company	-	785.40	785.40	-
Funding capital expenditure for the Proposed Expansion	827.02	620.00	120.00	500.00
General corporate purposes	-	16.21	16.21	
Total	827.02	1,421.61	921.61	500.00

(ii) Actual utilization:

(Rs. in million)

Item Head	Amount as proposed	Amount utilized			Total unutilized Amount	
	in Offer As at Document Beginning of the quarter March31, 2024		During the quarter March 31, 2024	At the end of the quarter March 31, 2024		
Repayment/prepaymentofcertainborrowingsofcompanyour	#785.4	##785.4	_	##785.4	NIL	
Funding capital expenditure for the Proposed Expansion	#620	\$461.50	*158.50	**620.00	NIL	
General corporate purposes	^20.47	^^20.47	-	^^20.47	NIL	
Offer related expenses in relation to the Fresh issue	###71.14	71.14	-	71.14	NIL	

Source: Monitoring Agency Report dated May 09, 2024 for the quarter ended on March 31, 2024..

Excluding interest earned if any on temporary deployment of fund pending utilization

Excluding utilisation of interest earned of Rs. 0.08 million on deployment of fund

^ Revised from Rs 16.21 million . Excluding interest earned if any on temporary deployment of fund pending utilisation

^*Excluding utilisation of interest earned of Rs. 0.29 million on deployment of fund.

Revised from Rs 74.73 million. Excluding interest earned if any on temporary deployment of fund pending utilisation

\$Excluding utilisation of interest earned of Rs.38.42 million on deployment of fund pending utilisation *Excluding utilisation of interest earned of Rs. 0.64 million on deployment of fund

**Excluding Interest utilisation of Rs. 39.06 million



(iii) Reasons for deviation, if any: There is no deviation in the utilisation of IPO Proceeds. Only the period for utilisation has been extended up to end of Fiscal year 2024 to use the IPO proceeds in a fungible/interchangeable manner along with the utilisation lor Machines & Moulds by way of approval of .the shareholder of the Company vide a special resolution through postal ballot on 31st August 2023 as follows ,:

Extension of time limit in deployment of funds received during IPO in a fungible/interchangeable manner along with the utilization for Machines and Moulds.

RESOLVED FURTHER THAT the consent of the members of the Company be and is hereby accorded to utilize the Unutilized Proceeds for the Funding Capital Expenditure for Proposed Expansion in a fungible /interchangeable manner along with the utilization for Machines and Moulds within Panchla facility as a separate sub head in addition to existing sub heads viz. Building civil work and exterior development work, clean room costs & Utilities and erection, limited to the overall limit of ₹ 827.02 million at the discretion of the Board."

Source: Monitoring Agency Report dated May 09, 2024 for the quarter ended on March 31, 2024.

11. Comments of monitoring agency, if applicable

 (a) Comments on use of funds (b) Comments on deviation, if any, in the use of proceeds of the issue from the objects stated in the offer document (c) Any other reservations expressed by the monitoring agency about the end use of funds 	There is no deviation in the utilisation of IPO Proceeds. Only the period for utilisation has been extended up to end of Fiscal year 2024 to use the IPO proceeds in a fungible/interchangeable manner along with the utilisation for Machines & Moulds
--	---

Source: Monitoring Agency Report dated May 09, 2024 for the quarter ended on March 31, 2024...

12. Pricing Data

Issue Price (Rs.): Designated Stock Exchange: Listing Date:

662.00 BSE November 26, 2021

Price parameters	At close of listing day (i.e.	At close of 30th calendar		As at the end of 1st FY after the listin of the issue (March 31, 2022)		
	November 26, 2021)	day from listing day**	calendar day from listing day	Closing price	High (during the FY)	Low (during the FY)
Market Price on Designated Stock Exchange (BSE)	840.00	634.45	632.45	704.2	928.65	570
BSE SENSEX	57,107.15	57124.31	57232.06	58568.51	62245.43	47204.5
Sectoral Index	NA	NA	NA	NA	NA	NA



	li	e end of 2nd F sting of the iss (March 31, 202	sue	As at the end of 3rd FY after the listi the issue (March 31, 2024)		
Price parameters	Closing price	High (during the FY)	Low (during the FY)	Closing price	High (during the FY)	Low (during the FY)
Market Price on Designated Stock Exchange (BSE)	532.75	914.35	501.5	394.05	646.35	390.45
BSE SENSEX	58991.52	63583.07	50921.22	73651.35	74245.17	58793.08
Sectoral Index	NA	NA	NA	NA	NA	NA

Source: BSE website

Since the 30th Calendar day is a holiday, the previous trading day has been considered.

13. Basis for Issue Price (Source of accounting ratios of peer group and industry average may be indicated; Source of the accounting ratios may generally be the same, however in case of different sources, reasons for the same may be indicated)

Accounting ratio		As disclosed in the offer document ⁽¹⁾	At the end of 1st FY (March 31, 2022) ⁽³⁾	At the end of 2nd FY (March 31, 2023) ⁽⁴⁾	At the end of 3rd FY (March 31, 2024) ⁽⁵⁾
EPS	Issuer:	-	-	-	
	Consolidated (Basic)	13.43	19.46	15.17	8.01
	Consolidated (Diluted)	13.43	19.46	15.17	8.01
	Peer Group ⁽³⁾ :	NA			
	Industry Avg:	NA	N.A	N.A	N.A
P/E	Issuer:				
	Consolidated (Basic)	49.29	36.19	35.12	49.19
	Consolidated (Diluted)	49.29	36.19	35.12	49.19
	Peer Group ⁽³⁾ :	NA	N.A	N.A	N.A
	Industry Composite:	NA	N.A	N.A	N.A
RoNW (%)	Issuer:				



	Consolidated	28.19	20.55	14.18	6.96
	Peer Group ⁽³⁾ :	NA	N.A	N.A	N.A
	Industry Composite:	NA	N.A	N.A	N.A
NAV	Issuer:				
	Consolidated	47.65	92.07	107.01	115.20
	Peer Group ⁽³⁾ :	NA	N.A	N.A	N.A
	Industry Avg:	NA	N.A	N.A	N.A

Notes:

- (1) Prospectus dated November 18, 2021
- (2) There are no listed companies in India that engage in a business similar to that of the Company. Accordingly, it is not possible to provide an industry comparison in relation to the Company
- (3) Financial Statements as submitted to the Stock Exchange for the financial year ended March 31, 2022.
- (4) Financial Statements as submitted to the Stock Exchange for the financial year ended March 31, 2023
- (5) Financial Statements as submitted to the Stock Exchange for the financial year ended March 31, 2024

Other notes

Pursuant to a resolution passed by our Board on June 14, 2021, and a resolution passed by our Shareholders in the EGM held on June 16, 2021, the Company has sub-divided its authorised share capital, such that 20,000,000 equity shares of \exists 10 each aggregating to \exists 200,000,000 were sub-divided and reclassified as 10,0000,000 Equity Shares of \exists 2 each aggregating to \exists 200,000,000. Therefore, the cumulative number of issued, subscribed and paid-up Equity Shares, pursuant to sub-division was increased from 192,228 equity shares of \exists 10 each to 961,140 Equity Shares of \exists 2 each. Stock split of shares are retrospectively considered for the computation of EPS in accordance with Ind AS 33 for the period mentioned above

The Board of Directors of the Company pursuant to a resolution dated June 14, 2021, and the shareholders pursuant to special resolution dated June 16, 2021 have approved the issuance of 52 bonus shares of face value \gtrless 2 each for every one existing fully paid up equity share of face value \gtrless 2 each and accordingly bonus shares were issued and allotted. Bonus shares are retrospectively considered for the computation of EPS in accordance with Ind AS 33 for the period mentioned above



14. Any other material information

	P	Particulars		Date
The Company has inforr tendered his resignation Company w.e.f. January	January 11, 2022			
The Company has infor Agarwal (Membership N	February 7, 2022			
from 7th February, 2022		the credit rating of the	Company undertaken by	March 29, 2022
CARE Ratings Limited ha		the treat rating of the		
Facilities	Existing rating	Revised Rating	Rating Action	
Long Term Bank Facilities	-	CARE A+ Stable	Assigned	
Long Term Bank Facilities	CARE A Stable	CARE A+ Stable	Upgraded	
Short Term Bank Facilities	-	CARE A1	Assigned	
The Company has inforr Understanding (MOU) Government of India (B Company at Amta, How The Company has infor CARE Ratings Limited ha	June 14, 2022 November 7, 2022			
Facilities	Existing rating	Revised Rating	Rating Action	
Long Term Bank Facilities	-	CARE A+ Stable	Assigned	
Long Term Bank Facilities	CARE A+ Stable	CARE A+ Stable	Reaffirmed	
Long Term/Short Term Bank Facilities	-	CARE A+ Stable/CARE A1+	Assigned	
Short Term Bank Facilities		CARE A1+	Assigned	
Short Term Bank Facilities	CARE A1	CARE A1+	Upgraded from CARE A1 (A One)	
Singapore to engage in i limited to the acquisition	investment activities rel on of other companies, or any other activities r	lated to the business of T Joint Ventures, Strategic	I Subsidiary of Tarsons in arsons, including but not c Partnerships and other o the business objectives	November 11, 202
The Company has inforr	ned about passed an or	•	nmissioner of CGST & CX npany, the details of the	November 16, 202
	ection 73(9) of the CGS	T Act, 2017 and Interest	Thousand Four Hundred t at the appropriate rate	
			nree Lakhs Ninety-Eight unt of Rs. 1,00,12,593/-	



(Rupees One Crore Twelve Thousand Five Hundred and Ninety-Three only) along with interest and penalties as proposed in the Show Cause Cum Demand Notice under Section 73(1) read with Rule 121 of CGST Rules, 2017.				
3. Imposition of penalty of Rs. 6,61,441/- (Rupees Six Lakh Sixty-One Thousand Four Hundred and Forty-One only) u/s 122(2)(a) read with Section 73(9) of CGST Rules, 2017.				
The Company has informed about the approval to make investments of up to maximum 13 million euros either by the way of subscription to the shares or through paying the existing loans to Wholly Owned Subsidiary Tarsons Life Science Pte Ltd.				
The Company has informed about the Share Purchase & Transfer Agreement entered with Nerbe R&D GmbH and Nerbe plus GmbH & Co. KG ("German Entities" or "Target Entities") on 20th December, 2023 by the Company & Tarsons Life Science Pte Ltd. ("TLSPL") i.e. a wholly owned subsidiary of the Company.				
The Company has informed about the reaffirmation/assign of credit rating as follows :				
Amount (₹ crores) 398.68 (Enhanced from 180.56)	Rating CARE A+ (RWD)	Rating Action Placed on Rating Watch with Developing Implications		
50.00	CARE A+ / CARE A1+ (RWD)	Assigned		
15.00	CARE A+ / CARE A1+ (RWD)	Placed on Rating Watch with Developing Implications		
29.00	CARE A1+ (RWD)	Assigned		
10.00	CARE A1+ (RWD)	Placed on Rating Watch with Developing Implications		
 The Company has informed about the receipt of an order dated 30th April, 2024 ("Order") from the Senior Joint Commissioner of Revenue of Directorate of Commercial Tax under Section 73 of West Bengal Good and Services Tax Act, 2017 ("the Act"), the details are as follows: 1. Demand for GST & Cess amounting to ₹ 68,04,061 (Rupees Sixty-Eight Lakhs Four Thousand and Sixty-One) and interest at the appropriate rate. 2. Imposition of Penalty of ₹ 6,80,476 (Rupees Six Lakhs Eighty Thousand Four Hundred and Sixty-One) 				
	ed in the Show Cause Cur 2017. of Rs. 6,61,441/- (Rupees (2)(a) read with Section T med about the approva- he way of subscription to diary Tarsons Life Science ned about the Share Purce plus GmbH & Co. KG (" Company & Tarsons Life iny. ned about the reaffirmat Amount (₹ crores) 398.68 (Enhanced from 180.56) 50.00 15.00 15.00 29.00 10.00 10.00 cervices Tax Act, 2017 (" ST & Cess amounting to ixty-One) and interest at	ed in the Show Cause Cum Demand Notice under 2017. of Rs. 6,61,441/- (Rupees Six Lakh Sixty-One Thom (2)(a) read with Section 73(9) of CGST Rules, 201 rmed about the approval to make investments he way of subscription to the shares or through p diary Tarsons Life Science Pte Ltd. ned about the Share Purchase & Transfer Agreem plus GmbH & Co. KG ("German Entities" or "To Company & Tarsons Life Science Pte Ltd. ("TLSI my. ned about the reaffirmation/assign of credit rati Amount (₹ crores) Rating 398.68 (Enhanced from 180.56) CARE A+ / CARE A1+ (RWD) 15.00 CARE A+ / CARE A1+ (RWD) 10.00 CARE A+ / CARE A1+ (RWD) 10.00 CARE A1+ (RWD)	ed in the Show Cause Cum Demand Notice under Section 73(1) read with 2017. of Rs. 6,61,441/- (Rupees Six Lakh Sixty-One Thousand Four Hundred and (2)(a) read with Section 73(9) of CGST Rules, 2017. med about the approval to make investments of up to maximum 13 he way of subscription to the shares or through paying the existing loans diary Tarsons Life Science Pte Ltd. med about the Share Purchase & Transfer Agreement entered with Nerbe plus GmbH & Co. KG ("German Entities" or "Target Entities") on 20th Company & Tarsons Life Science Pte Ltd. ("TLSPL") i.e. a wholly owned iny. med about the reaffirmation/assign of credit rating as follows : <u>Amount (₹ crores)</u> Rating Rating Action 398.68 (Enhanced from CARE A+ (RWD) Placed on Rating Watch 180.56) 15.00 CARE A+ / CARE A1+ Assigned (RWD) 15.00 CARE A+ / CARE A1+ Placed on Rating Watch with Developing Implications 29.00 CARE A1+ (RWD) Assigned 10.00 CARE A1+ (RWD) Placed on Rating Watch with Developing Implications 29.00 CARE A1+ (RWD) Assigned 10.00 CARE A1+ (RWD) Ass	

Source- Stock Exchange Filings

All the above information has been updated till May 30, 2024 unless indicated otherwise